<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/">
  <channel>
    <title>Undruggable on Tenu Tech Brief</title>
    <link>https://cluster-site.onrender.com/tags/undruggable/</link>
    <description>Recent content in Undruggable on Tenu Tech Brief</description>
    <generator>Hugo -- 0.146.0</generator>
    <language>en-us</language>
    <lastBuildDate>Tue, 24 Feb 2026 06:04:26 +0000</lastBuildDate>
    <atom:link href="https://cluster-site.onrender.com/tags/undruggable/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>Novartis Commits $100M to Startup With Tech That Brings Peptides to Undruggable Targets</title>
      <link>https://cluster-site.onrender.com/posts/novartis-commits-100m-to-startup-with-tech-that-brings-peptides-to-undruggable-targets/</link>
      <pubDate>Thu, 19 Feb 2026 20:47:39 +0000</pubDate>
      <guid>https://cluster-site.onrender.com/posts/novartis-commits-100m-to-startup-with-tech-that-brings-peptides-to-undruggable-targets/</guid>
      <description>• Novartis&amp;rsquo;s alliance with Unnatural Products is pursuing next-generation peptide drugs for cardiovascular disease. • The startup already has drug R&amp;amp;D alliances with BridgeBio Phar</description>
    </item>
  </channel>
</rss>
